Technetium (99mTc) exametazime

Technetium (^99mTc) exametazime

File:Tc-99m exametazime skeletal.svg
Systematic (IUPAC) name
[[(3RS,3'RS)-3,3'-[(2,2-Dimethyltrimethylene)diimino][di-2-butanone]dioximato](3-)-N,N',N'',N''']oxotechnetium (99mTc)
Clinical data
Trade names	Ceretec
Licence data	US FDA:link
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Intravenous
Identifiers
CAS Number	Template:CAS (exametazime)
ATC code	V09AA01 (WHO) V09HA02 (labelled leucocytes)
PubChem	CID: 9552069
UNII	3B744AG22N Y
Chemical data
Formula	C13H25N4O3Tc
Molecular mass	384.3655 g/mol
(verify)

Technetium (^99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. Exametazime (the part without technetium) is sometimes referred to by its chemical name of hexamethylpropyleneamine oxime or HMPAO.

Chemistry

File:Exametazime.png

Exametazime (hexamethylpropyleneamine oxime, HMPAO)

The drug consists of two of the three stereoisomers of hexametazime (HMPAO), one of which is shown here, the other being its enantiomer. The third stereoisomer is the meso form. Exametazime acts as a chelating agent for the radioisotope technetium-99m.

External links

• European Association of Nuclear Medicine: Ceretec
• GE Healthcare: Ceretec
• Exametazime ligand: CID 9552071 from PubChem